Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
R Berardi, M Santoni, F Morgese… - OncoTargets and …, 2013 - Taylor & Francis
In the last decade, better understanding of the role of epidermal growth factor receptor in the
pathogenesis and progression of non-small cell lung cancer has led to a revolution in the …
pathogenesis and progression of non-small cell lung cancer has led to a revolution in the …
[PDF][PDF] Breast cancer-new aspects of tumor biology: are calcitriol and cyclooxygenase-2 possible targets for breast cancer?
M Thill, A Terjung, M Friedrich - Eur. J. Gynaec. Oncol.-ISSN, 2014 - oss.ejgo.net
Up until now there have been many advances in treatment options for breast cancers such
as targeted therapies like monoclonal antibodies, tyrosine kinase inhibitors, mTOR …
as targeted therapies like monoclonal antibodies, tyrosine kinase inhibitors, mTOR …
[HTML][HTML] Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1β signal pathway up-regulates cyclooxygenase-2 gene expression …
KY Chang, MR Shen, MY Lee, WL Wang, WC Su… - Journal of Biological …, 2009 - ASBMB
Hypoxia-inducible factor (HIF) accumulates when tumors grow under hypoxic conditions.
The genesis of tumors, however, usually involves normoxic conditions. In this study, we were …
The genesis of tumors, however, usually involves normoxic conditions. In this study, we were …
Biomarker‐based phase I dose‐escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell …
K Reckamp, B Gitlitz, LC Chen, R Patel, G Milne… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Apricoxib, a novel once‐daily selective cyclooxygenase‐2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines
M Thill, D Fischer, S Becker, T Cordes… - Anticancer …, 2009 - ar.iiarjournals.org
Background: The antiproliferative effects of calcitriol (1, 25 (OH) 2D3) mediated via the
vitamin D receptor (VDR), render the biologically active form of vitamin D a promising target …
vitamin D receptor (VDR), render the biologically active form of vitamin D a promising target …
[HTML][HTML] Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo
H Zhang, Z Li, K Wang, P Ren - Oncology Reports, 2015 - spandidos-publications.com
X-linked inhibitor of apoptosis protein (XIAP) has been shown to be highly expressed in lung
cancer, but not in normal lung tissue, which makes it an attractive target for lung cancer …
cancer, but not in normal lung tissue, which makes it an attractive target for lung cancer …
Improved cancer specific‐survival in patients with carcinoma invading bladder muscle expressing cyclo‐oxygenase‐2
A Aziz, A Lessard, K Moore, H Hovington… - BJU …, 2011 - Wiley Online Library
Study Type–Prognosis (case series) Level of Evidence 4 OBJECTIVE To determine whether
the expression of cyclo‐oxygenase (COX)‐2 has an influence on survival and on the …
the expression of cyclo‐oxygenase (COX)‐2 has an influence on survival and on the …
Targeting the eicosanoid pathway in non-small-cell lung cancer
L Horn, M Backlund, DH Johnson - Expert opinion on therapeutic …, 2009 - Taylor & Francis
Multiple lines of evidence suggest that cyclooxygenase-2 (COX-2) upregulation is an early
event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with …
event in the development of non-small-cell lung cancer. Preclinical data indicate tumors with …